Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label multicenter study of HS-IT101 injection in advanced melanoma
CTR20260340Phase 2Active
- Sponsor
- Huasai Boman
- Start
- Jan 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of HS-IT101 in melanoma, sponsored by Huasai Boman. Started Jan 2026; status: active.
02
Drugs
HS-IT101
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20260340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260340.